Interrupción Temporaria de Baricitinib: Caracterización de las Interrupciones y Efecto en los Desenlaces Clínicos de los Pacientes con Artritis Reumatoide
Arth Res Ther 2020;22:115 doi.org/10.1186/s13075-020-02199-8
This study aimed to characterize temporary interruptions of baricitinib and describe their impact on efficacy and safety. Brief interruptions during phase 3 baricitinib trials were associated with minor increases in symptoms which were resolved following treatment. In life-long, chronic conditions such as RA, interruption of therapy is common for various reasons, such as side effects, non-compliance, or because a patient requires surgery. Concerns have been raised that these treatment breaks cou...